Alternatives to Adocia

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Biotechnology company developing and commercializing cell therapies for cancer treatment.

Biotechnology company focused on developing cancer immunotherapies.

Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing novel therapeutics to restore gut lymphatic function.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Biopharmaceutical company developing and commercializing CNS disease treatments.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Developing in vivo immunotherapies for autoimmune diseases and cancer.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A global leader in clinical pharmacology and bioanalytical sciences.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A clinical-stage biotechnology company developing in vivo gene editing therapies.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A biotechnology company developing genetic therapies for rare disorders.

Accelerating patient access to evidence-based innovation in mental health.

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.